Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Melanoma metastasis remains a significant clinical challenge with limited therapeutic options.
• The liver-X nuclear hormone receptor (LXR) pathway is implicated in various cellular processes, but its role in melanoma has not been fully elucidated.

Purpose of the Study:

• To investigate the liver-X nuclear hormone receptor (LXR) as a potential therapeutic target for preventing and treating melanoma metastasis.
• To elucidate the molecular mechanisms underlying LXR's effects on melanoma progression and metastasis.

Main Methods:

• Pharmacologic administration of LXR agonists in melanoma models.
• Molecular analyses including gene expression and protein analysis.
• Genetic studies involving LXRβ manipulation.
• Assessment of tumor growth, invasion, angiogenesis, and metastasis in vivo.
• Evaluation of combination therapy with standard melanoma treatments.

Main Results:

• Oral LXR agonists significantly suppressed melanoma invasion, angiogenesis, tumor progression, and metastasis.
• LXRβ activation was identified as the key mediator, inducing apolipoprotein-E (ApoE) in tumor and stromal cells.
• LXRβ agonism demonstrated efficacy across diverse melanoma mutational backgrounds and prolonged survival.
• LXRβ activation showed synergistic effects with dacarbazine, B-Raf inhibitors, and anti-CTLA-4 antibodies, overcoming resistance.

Conclusions:

• The liver-X nuclear hormone receptor (LXR), specifically LXRβ, represents a viable therapeutic target for melanoma.
• LXRβ activation, through ApoE induction, effectively inhibits melanoma metastasis and tumor growth.
• LXRβ targeting offers a promising strategy, potentially enhancing current melanoma therapies and overcoming drug resistance.